Free Trial
→ Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse (From Priority Gold) (Ad)
NASDAQ:CNTA

Centessa Pharmaceuticals Q3 2023 Earnings Report

Centessa Pharmaceuticals logo
$12.08 +0.07 (+0.62%)
Closing price 05/7/2025 03:59 PM Eastern
Extended Trading
$12.60 +0.52 (+4.27%)
As of 08:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Centessa Pharmaceuticals EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.46
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Centessa Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Centessa Pharmaceuticals Announcement Details

Quarter
Q3 2023
Date
11/13/2023
Time
N/A
Conference Call Date
Monday, November 13, 2023
Conference Call Time
6:46AM ET

Upcoming Earnings

Centessa Pharmaceuticals' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q1 2025 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

Centessa Pharmaceuticals' Q3 2023 Press ReleasePress Release
(8-K)
Centessa Pharmaceuticals' Q3 2023 Quarterly reportQuarterly report
(10-Q)

Centessa Pharmaceuticals Earnings Headlines

Is Centessa Pharmaceuticals plc (CNTA) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
May 5 at 8:07 AM | insidermonkey.com
Analysts Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Price Target at $27.71
May 5 at 1:35 AM | americanbankingnews.com
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
May 8, 2025 | Timothy Sykes (Ad)
Relative Strength Alert For Centessa Pharmaceuticals
April 3, 2025 | nasdaq.com
Morgan Stanley Remains a Buy on Centessa Pharmaceuticals (CNTA)
April 2, 2025 | markets.businessinsider.com
Piper Sandler Initiates Coverage of Centessa Pharmaceuticals plc - Depositary Receipt () (CNTA) with Overweight Recommendation
March 31, 2025 | msn.com
See More Centessa Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Centessa Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Centessa Pharmaceuticals and other key companies, straight to your email.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals (NASDAQ:CNTA), a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

View Centessa Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles